Does Free Bacteriostatic Water Save Money on Retatrutide?
Retatrutide listings that include free bacteriostatic water look cheaper upfront, but the real cost per mg depends on concentration, vial size, and waste.
Reviewed by Marcus Webb, PhD, research pharmacologist ·
Marcus Webb, PhD is a research pharmacologist with a doctorate from Johns Hopkins University and over 12 years of experience in receptor-selective peptide analogs, bioavailability science, and the pharmacoeconomics of emerging therapeutic compounds.
- cost
- reconstitution
- retatrutide
A retatrutide listing that includes free bacteriostatic water is not automatically the better deal. Bundling the diluent into the price only saves money if the seller’s markup on the powder is smaller than what the buyer would otherwise pay to source bacteriostatic water separately. In many cases the “free” line item is absorbed into a higher headline price, and the effective cost per mg ends up close to, or above, a listing that sells the diluent separately.
Why Sellers Bundle Bacteriostatic Water
Bacteriostatic water is a low-cost item relative to a retatrutide vial. A single multi-use bottle typically reconstitutes many vials of lyophilized powder, so its marginal cost per use is small. Listing it as a free inclusion is an easy way to make an offer look more complete without meaningfully changing the seller’s margin. That is not inherently deceptive — it can simplify the buyer’s checklist — but it does not tell you anything about whether the total price is competitive.
The number that matters for comparing listings is not “does this include free bacteriostatic water,” but the effective cost per mg once every input, including the diluent, is accounted for.
What “Free” Actually Means in a Listing Price
When a listing advertises free bacteriostatic water, the cost of that water has already been folded into the price of the vial. The question worth asking is how much that inclusion actually adds, versus how much a buyer would spend by sourcing bacteriostatic water on their own. If a multi-use bottle of bacteriostatic water costs a fixed amount and reconstitutes many vials over time, its true incremental cost per vial is a fraction of the bottle price — often well under a dollar. A listing that prices in “free” water at a much higher implied cost is not passing along a discount; it is charging for convenience.
A Worked Comparison
Consider two listings for the same 10 mg retatrutide vial from different sources.
| Listing | Powder price | Bacteriostatic water | Effective diluent cost added | Total effective cost | Cost per mg |
|---|---|---|---|---|---|
| A — water sold separately | $150.00 | Not included; buyer uses a 30 mL multi-use bottle priced at $12.00 | $0.80 (2 mL drawn from the 30 mL bottle) | $150.80 | $15.08 |
| B — water bundled “free” | $165.00 | Included, 3 mL single-use vial | $0.00 charged separately, priced into the $165.00 | $165.00 | $16.50 |
Working through Listing A: a 30 mL bottle of bacteriostatic water at $12.00 costs $0.40 per mL ($12.00 ÷ 30 mL). Reconstituting the 10 mg vial with 2 mL uses 2 × $0.40, or $0.80 of that bottle. Added to the $150.00 powder price, the effective total is $150.80, or $15.08 per mg ($150.80 ÷ 10 mg).
Working through Listing B: the $165.00 price already includes the diluent, so the effective total is simply $165.00, or $16.50 per mg ($165.00 ÷ 10 mg).
Rechecking both: $150.00 + $0.80 = $150.80, and $150.80 ÷ 10 = $15.08. Then $165.00 ÷ 10 = $16.50. Listing B, the one that includes free bacteriostatic water, costs $1.42 more per mg than Listing A, where the buyer sources the diluent separately. The free inclusion did not translate into savings here — it masked a higher powder price.
This is a single hypothetical pair of numbers, not a claim about any specific seller’s current pricing. The method — dividing the all-in price by the mg quantity — is what should be applied to any real listing before comparing it to another.
Concentration Is a Separate Variable From Price
Bundled bacteriostatic water often comes in a fixed volume chosen by the seller, which sets the reconstituted concentration whether or not that volume matches what the buyer would have chosen. Concentration is calculated as vial mg divided by mL of bacteriostatic water added. For a 10 mg vial reconstituted with 2 mL, the concentration is 10 mg ÷ 2 mL, or 5 mg/mL. On a U-100 insulin syringe, where 1 mL equals 100 units, that works out to 1 mg per 20 units (100 units ÷ 5 mg). A different bundled volume — 3 mL instead of 2 mL — produces 10 mg ÷ 3 mL, or roughly 3.33 mg/mL, changing the units-per-mg ratio accordingly. A free inclusion that locks in an inconvenient volume is a separate cost consideration from the price itself, since it can mean drawing up more or less diluent than a buyer would otherwise choose. Reconstitution calculators, such as the one at peptcalc.com, can be used to check the units-per-mg outcome for any combination of vial size and diluent volume before comparing listings.
What to Check Before Assuming a Bundle Is Cheaper
A few line items determine whether a retatrutide listing that includes free bacteriostatic water actually saves money compared to one that does not:
- The total price divided by the mg quantity, not the sticker price alone.
- The volume of bacteriostatic water bundled, since it sets the concentration and whether it matches a buyer’s preferred draw volume.
- The price of bacteriostatic water purchased separately, and how many vials one multi-use bottle can reconstitute, which determines its true marginal cost per vial.
- Whether the listing’s per-mg price, once the diluent is accounted for, is actually lower than a comparable listing that prices the powder and water separately.
The broader class of compounds retatrutide belongs to — triple agonists acting on GLP-1, GIP, and glucagon pathways — has been the subject of pharmacology reviews describing formulation and receptor activity, including a 2024 review of hunger-pathway pharmacology across GLP-1, GIP, and glucagon receptor agonists. Retatrutide’s own development pathway, including expanded-access protocols under its compound designation LY3437943, is documented in public trial registries and gives context for how the compound is formulated and studied outside of any specific commercial listing.
Summary
A retatrutide listing that includes free bacteriostatic water is not automatically cheaper, and it is not automatically more expensive — it depends on how much the seller charged for the powder relative to what the diluent would have cost on its own. Comparing listings on a straight cost-per-mg basis, after accounting for any bundled diluent, is the only way to know whether “free” reflects a real discount or an offsetting price increase elsewhere in the listing.
Sources: a 2024 review of GLP-1, GIP, and glucagon receptor agonists for obesity treatment and the expanded access protocol for retatrutide (LY3437943) registered on ClinicalTrials.gov.